14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
IDNA vs IHAK: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, iShares Cybersecurity and Tech ETF (IHAK) is the stronger overall head-to-head candidate over iShares Genomics Immunology and Healthcare ETF (IDNA) in the Tradestie Institutional Equity Comparison Engine, winning 2–1 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). IDNA carries a Unified Composite Score of 41.7/100 (SELL) at $39.25 (N/M Forward P/E, N/A operating margin), whereas IHAK carries 55.0/100 (HOLD) at $67.66 (N/M Forward P/E, N/A operating margin).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IDNA vs IHAK. Trailing 12-month operating profitability (IDNA N/A vs IHAK N/A) and valuation multiples (IDNA N/M vs IHAK N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ IDNA vs IHAK Key Questions & Quantitative Answers
As of Nov 16, 2026, iShares Cybersecurity and Tech ETF (IHAK) is the stronger overall head-to-head candidate over iShares Genomics Immunology and Healthcare ETF (IDNA) in the Tradestie Institutional Equity Comparison Engine, winning 2–1 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). IDNA carries a Unified Composite Score of 41.7/100 (SELL) at $39.25 (N/M Forward P/E, N/A operating margin), whereas IHAK carries 55.0/100 (HOLD) at $67.66 (N/M Forward P/E, N/A operating margin). Technically, IDNA sits in a Neutral phase (RSI 41.3, UNCLASSIFIED options structure) and IHAK sits in a Neutral phase (RSI 44.9, UNCLASSIFIED options structure).
IDNA and IHAK split Growth & Scale metrics: IDNA posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with IHAK at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, IDNA generates N/A in USD-normalized revenue versus N/A for IHAK. In operating R&D and SG&A reinvestment, IDNA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for IHAK.
IDNA and IHAK trade at balanced relative valuation multiples. IDNA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas IHAK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IDNA (N/A ROE) versus IHAK (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, IDNA carries 44.7% implied volatility (20th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.17β · 44% Vol realized risk). By comparison, IHAK carries 22.7% implied volatility (5th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.05β · 39% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.